Docetaxel—a taxane-based chemotherapeutic agent—was the first treatment to demonstrate significant improvements in overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, the response to docetaxel is generally short-lived, and relapse eventually occurs due to the development of resistance. To explore the mechanisms of acquired docetaxel resistance in prostate cancer (PCa) and set these in the context of androgen deprivation therapy, we established docetaxel-resistant PCa cell lines, derived from the androgen-dependent LNCaP cell line, and from the LNCaP lineage-derived androgen-independent C4-2B sub-line. We generated two docetaxel-resistant LNCaPR and C4-2BR sub-lines, with IC50 values 77- and 50-fold higher than those of the LNCaP and C4-2B parental cells, respectively. We performed gene expression analysis of the matched sub-lines and found several alterations that may confer docetaxel resistance. In addition to increased expression of ABCB1, an ATP-binding cassette (ABC) transporter, and a well-known gene associated with development of docetaxel resistance, we identified genes associated with androgen signaling, cell survival, and overexpression of ncRNAs. In conclusion, we identified multiple mechanisms that may be associated with the development of taxane drug resistance in PCa. Actioning these mechanisms could provide a potential approach to re-sensitization of docetaxel-resistant PCa cells to docetaxel treatment and thereby further add to the life-prolonging effects of this drug in men with mCRPC.
Nyuzenamides belong to a class of bioactive cinnamoyl moieties containing nonribosomal peptides. Genome mining revealed a putative nyu BGC in Streptomyces hygroscopicus DSM 40578. Two new analogues, nyuzenamides D (1) and E (2), were subsequently isolated, and their structures were elucidated by detailed nuclear magnetic resonance spectroscopic and mass spectrometric data analyses. The absolute configuration of 1 was determined by a single-crystal X-ray diffraction study. Through retrobiosynthesis and CRISPR genome editing, the nonribosomal peptide synthetase biosynthetic gene cluster for nyuzenamides was confirmed. Nyuzenamides D and E are likely derived from nyuzenamide C through nonenzymatic hydrolysis. Our discovery enriches the diversity of cinnamoyl-containing nonribosomal peptides and validates the biosynthetic gene clusters for future genome mining research.
Lysolipin I ( 1 ) is a highly bioactive xanthone with strong antibacterial and cytotoxic properties. Given the limited number of lysolipin analogues, discovery of new natural lysolipin derivatives is important for understanding their structure-activity relationships. A soil-derived Streptomyces sp. P8-2B18 harbors a putative lysolipin biosynthetic gene cluster and LC-MS based metabolomic analysis revealed the production of lysolipin I along with unreported analogues. Large-scale fermentation followed by isolation led to the discovery of four new analogues, lysolipins J-M ( 2 – 5 ), the structures of which were elucidated by mass spectrometric and NMR spectroscopic data analyses. Lysolipin L features a five-membered lactam F ring, which was unprecedented in reported lysolipins. Lysolipin M has a novel skeleton, with an extra methyl (Me-36) and a glycosyl group replacing a 1,3-oxane ring in lysolipin I. While lysolipins I, J and K displayed strong activity against Staphylococcus aureus and Aspergillus flavus with MIC values ranging from 0.25 to 4 μg/mL and lysolipin L showed only moderate activities, lysolipin M was inactive (>50 μg/mL). Lysolipins I–K showed potent cytotoxic activity against prostate cancer cell lines LNCaP and C4-2B, with IC 50 values in the submicromolar range. In contrast, lysolipin L exhibited no cytotoxicity and lysolipin M exhibited substantially reduced potency. Their broad, non-selective bioactivities restricted their applicability as therapeutic agents.
Isoquinolinequinones represent an important family of natural alkaloids with profound biological activities. Heterologous expression of a rare bifunctional indole prenyltransferase /tryptophan indole-lyase enzyme from Streptomyces mirabilis P8-A2 in S. albidoflavus J1074 led to the activation of a putative isoquinolinequinone biosynthetic gene cluster and production of a novel isoquinolinequinone alkaloid, named maramycin ( 1 ). The structure of maramycin was determined by analysis of spectroscopic (1D/2D NMR) and MS spectrometric data. The prevalence of this bifunctional biosynthetic enzyme was explored and found to be a recent evolutionary event with only a few representatives in Nature. Maramycin exhibited moderate cytotoxicity against human prostate cancer cell lines, LNCaP and C4-2B. The discovery of maramycin ( 1 ) enriched the chemical diversity of natural isoquinolinequinones and also provided new insights into crosstalk between the host biosynthetic genes and the heterologous biosynthetic genes in generating new chemical scaffolds.